The effort seeks to cut down on “reporting-data noise that may mask true signals of significant adverse events.”
The effort seeks to cut down on “reporting-data noise that may mask true signals of significant adverse events.” The authors state that because FDA had until now not established a threshold of when adverse events should be reported, sponsors of clinical trials being conducted under investigational new drug (IND) applications were reporting an excess number of serious adverse events-often without clearly establishing whether or not those events were definitively related to the drug.
Additionally, the article authors point out, the adverse events reported were often already common in the study population or in the disease under investigation, regardless of drug therapy. “Under these circumstances, it is impossible to determine whether drug exposure is causally related to the event,” the article authors state.
With the new policy in place, the hope is that adverse reporting will become “more meaningful and relevant to patients’ safety,” the article authors state.
According to the authors, under the new rule’s guidelines, clinical investigators should:
The authors conclude by stating, “We believe that the new regulation will improve the quality of safety reporting and strengthen the FDA’s ability to monitor the safety of drug and biologic products. It will minimize reports that do not contribute to the understanding of a drug’s developing safety profile and decrease the number of uninterpretable reports.”
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.